Litigation Details for HORIZON PHARMA, INC. v. ACTAVIS LABORATORIES FL., INC. (D.N.J. 2016)
HORIZON PHARMA, INC. v. ACTAVIS LABORATORIES FL., INC. (D.N.J. 2016)
| Docket | ⤷ Start Trial | Date Filed | 2016-08-11 |
| Court | District Court, D. New Jersey | Date Terminated | 2017-01-10 |
| Cause | 35:271 Patent Infringement | Assigned To | Mary Little Cooper |
| Jury Demand | None | Referred To | Douglas Arpert |
| Patents | 8,945,621; 9,220,698; 9,345,695 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in HORIZON PHARMA, INC. v. ACTAVIS LABORATORIES FL., INC.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for HORIZON PHARMA, INC. v. ACTAVIS LABORATORIES FL., INC. (D.N.J. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-08-11 | External link to document | |||
| 2016-08-11 | 1 | The Patents-in-Suit 16. United States Patent No. 8,945,621 (“the ’621 patent”), entitled… ’621 patent. The ’621 patent will expire on October 17, 2031. 18. The ’621 patent is listed…the ’698 patent. The ’698 patent will expire on March 10, 2031. 21. The ’698 patent is listed… 38. The ’621 patent is a patent with respect to which a claim of patent infringement could reasonably…methods patented in the ’621 patent, constitutes a material part of the inventions of the ’621 patent, is | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
